GlassScriptPhysician profile
Muhammad A Kaleem
NPI 1285697078
$4,995.18
in general payments reported to CMS, 2019-2025
26 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $348 · 2021: $190 · 2022: $598 · 2023: $356 · 2024: $921 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816 · Education: $238 · Travel and Lodging: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.44 |
| Education | $238.22 |
| Travel and Lodging | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $926.90 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $639.17 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Intuitive Surgical, INC. | $527.07 | 2022-2025 | Da Vinci Surgical System |
| Genzyme Corporation | $427.45 | 2019-2025 | |
| Insmed, INC. | $364.81 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $338.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.57 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $245.93 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $186.46 | 2019-2020 | |
| Amgen INC. | $169.46 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $161.54 | 2020-2025 | Prolastin-C Liquid |
| Electromed, INC. | $126.48 | 2019-2025 | Smartvest |
| Philips North America LLC | $124.95 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pfizer INC. | $75.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.15 | 2023-2025 | Glassia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $56.88 | 2023-2024 | Yupelri |
| Csl Behring | $38.95 | 2020 | |
| Vifor Pharma, INC. | $33.64 | 2025 | Zemaira |
| Verona Pharma, INC. | $25.72 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $24.86 | 2023 | |
| Merck Sharp & Dohme LLC | $24.67 | 2019 | |
| United Therapeutics Corporation | $18.11 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.49 | 2023 | Nuzyra |
| Melinta Therapeutics, LLC | $16.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.49 | 2022 | |
| Astellas Pharma US INC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Kaleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.